Vimarsana
Biggest News Aggregation in the World

Page 3 - Scott Struthers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scott Struthers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scott Struthers Today - Breaking & Trending Today

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - Vimarsana News

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2024 -- Crinetics Pharmaceuticals, Inc. today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P....

Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study - Crinetics Pharmaceuticals (NASDAQ:CRNX) - Vimarsana News

Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study - Crinetics Pharmaceuticals (NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for 

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome - Vimarsana News

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.8% Following Insider Selling - Vimarsana News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.8% Following Insider Selling

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) traded down 3.8% during trading on Wednesday following insider selling activity. The company traded as low as $32.76 and last traded at $33.04. 482,383 shares were traded during trading, a decline of 37% from the average session volume of 770,039 shares. The stock had previously […]

Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth - Vimarsana News

Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth

Key Developments and Financial Performance for Third Quarter 2023

Source: yahoo.com